Resultados da pesquisa - (( ((drug de) OR (drug dose)) developp type ) OR ( drug doses develop type ))*

Pesquisas alternativas:
developp type » developing type (Expandir a Pesquisa), development type (Expandir a Pesquisa), developed ptypei (Expandir a Pesquisa)
doses develop » loss develop (Expandir a Pesquisa), posters develop (Expandir a Pesquisa), models develop (Expandir a Pesquisa)
develop type » developing type (Expandir a Pesquisa)
drug doses » drug disease (Expandir a Pesquisa)
drug dose » drug dosage (Expandir a Pesquisa)
drug de » drug dna (Expandir a Pesquisa)

A carregar...

Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials

Por Hansen, Aaron R., Cook, Natalie, Ricci, M. Stacey, Razak, Albiruni, Le Tourneau, Christophe, McKeever, Kathleen, Roskos, Lorin, Dixit, Rakesh, Siu, Lillian L., Hinrichs, Mary Jane
Publicado no Oncologist (2015)

Assuntos: “...New Drug Development and Clinical Pharmacology...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Pharmacokinetics and Drug Dosing in Obese Children

Por Kendrick, Jennifer G., Carr, Roxane R., Ensom, Mary H.H.
Publicado em 2010

“... using the following terms: obesity, morbid obesity, overweight, pharmacokinetics, drug, dose, kidney...”
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors

Por Leong, Stephen, Moss, Rebecca A., Bowles, Daniel W., Ware, Joseph A., Zhou, Jing, Spoerke, Jill M., Lackner, Mark R., Shankar, Geetha, Schutzman, Jennifer L., van der Noll, Ruud, Voest, Emile E., Schellens, Jan H.M.
Publicado no Oncologist (2017)

Assuntos: “...New Drug Development and Clinical Pharmacology...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development

Por Ahrén, Bo
Publicado no J Diabetes Investig (2018)

“... used in the management of type 2 diabetes. Their development emerged from the understanding that a...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Short Communication: A Repeated Simian Human Immunodeficiency Virus Reverse Transcriptase/Herpes Simplex Virus Type 2 Cochallenge Macaque Model for the Evaluation of Microbicides

Por Kenney, Jessica, Derby, Nina, Aravantinou, Meropi, Kleinbeck, Kyle, Frank, Ines, Gettie, Agegnehu, Grasperge, Brooke, Blanchard, James, Piatak, Michael, Lifson, Jeffrey D., Zydowsky, Thomas M., Robbiani, Melissa
Publicado em 2014

Assuntos: “...Preclinical Studies/Drug Development...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Development of a mobile application for vancomycin dosing calculation: A useful tool for the rational use of antimicrobials

Por Tácio de Mendonça Lima, Millena Padela da Silva, Luan Donato Silva Luz, Thais Cristina Amorim Estevão Soares, Etielle Silvestre Dantas, Gabriela Felix Teixeira, Rafael Henrique de Souza Costa, Sérgio Henrique Monte Santo Andrade
Publicado em 2022-03-01

Assuntos: “...Drug dosage calculation...”
Obter o texto integral

Artigo

A carregar...

Effect of Study Design on Sample Size in Studies Intended to Evaluate Bioequivalence of Inhaled Short‐Acting β‐Agonist Formulations

Por Zeng, Yaohui, Singh, Sachinkumar, Wang, Kai, Ahrens, Richard C.
Publicado no J Clin Pharmacol (2017)

Assuntos: “...Drug Development...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Oxazolone-Induced Delayed Type Hypersensitivity Reaction in the Adult Yucatan Pigs. A Useful Model for Drug Development and Validation

Por Nuhaily, Samer, Damaj, Bassam B., Maghazachi, Azzam A.
Publicado em 2009

“... of therapeutic modalities of newly developed anti-inflammatory drugs. The pigs were sensitized with oxazolone, re...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Improving Conventional or Low Dose Metronomic Chemotherapy with Targeted Antiangiogenic Drugs

Por Kerbel, Robert S.
Publicado em 2007

“... low dose chemotherapy. We have been studying the hypothesis that some chemotherapy drugs at maximum...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A...

Por Gu, Tianwei, Hong, Ting, Zhang, Pengzi, Tang, Sunyinyan, Bi, Yan, Lu, Hai, Men, Lichuang, Ma, Dongwei, Zhu, Dalong
Publicado no Diabetes Ther (2018)

“... was developed. RESULTS: The dose of Gla-100 at week 24 was negatively correlated with age and positively...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Dose‐Finding Studies Among Orphan Drugs Approved in the EU: A Retrospective Analysis

Por Schuller, Yvonne, Gispen‐de Wied, Christine, Hollak, Carla E. M., Leufkens, Hubertus G. M., Stoyanova‐Beninska, Violeta
Publicado no J Clin Pharmacol (2018)

Assuntos: “...Orphan Drugs...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Development of an Optimized Dose for Coformulation of Zidovudine with Drugs That Select for the K65...

Por Hurwitz, Selwyn J., Asif, Ghazia, Kivel, Nancy M., Schinazi, Raymond F.
Publicado em 2008

“... immunodeficiency virus type 1 polymerase region. Furthermore, other novel non-thymine nucleoside reverse...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Impact of dextrose dose on hypoglycemia development following treatment of hyperkalemia

Por Farina, Nicholas, Anderson, Christopher
Publicado no Ther Adv Drug Saf (2018)

“... examined the impact of altering the insulin dose administered on hypoglycemia development; no trials...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Accelerating Drug Development Using Biomarkers: A Case Study with Sitagliptin, A Novel DPP4 Inhibitor for Type 2 Diabetes

Por Krishna, Rajesh, Herman, Gary, Wagner, John A.
Publicado em 2008

Assuntos: “...Review Article/Theme: Role of Biomarkers in Drug Development/Guest Editors: Brian P. Booth...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors

Por Jardim, Denis L., de Melo Gagliato, Débora, Giles, Francis J., Kurzrock, Razelle
Publicado no Clin Cancer Res (2017)

“... drug development/approval models on the accuracy of safety and efficacy assessments by searching the US...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Development of drug resistance in a murine mammary tumour.

Por McMillan, T. J., Stephens, T. C., Steel, G. G.
Publicado em 1985

“... delay and clonogenic cell survival during repeated drug treatment. A slow rate of resistance development...”
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates

Por Kamath, Amrita V., Iyer, Suhasini
Publicado no Pharm Res (2014)

“...Antibody drug conjugates (ADCs) are an emerging new class of targeted therapeutics for cancer...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Drug related problems in elderly patients with type 2 diabetes mellitus

Por S Z Inamdar, R V Kulkarni
Publicado em 2016-01-01

Assuntos: “...Drug related problems...”
Obter o texto integral

Artigo

A carregar...

Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?

Por Smith, R.J
Publicado em 2005

“... are used to develop a prescription to minimize the emergence of drug-resistance for protease-sparing...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

A carregar...

Alzheimer’s Disease Drug Development in 2008 and Beyond: Problems and Opportunities

Por Becker, Robert E., Greig, Nigel H.
Publicado em 2008

“... risks we considered the relevance to AD drug development of the following factors: (1) effective dosing...”
Obter o texto integral
Obter o texto integral

Artigo

1
2
3
4
5
6
7
8
9
10
11
Seguinte
[93]

Refinar a Pesquisa